SABI Mind and Reverie Psychedelics have partnered to expand research into psychedelic-assisted therapies.
Delic Holdings Corp subsidiary, Delic Labs, has received a Health Canada 56 Research Exemption that will allow scientists to conduct research and perform tests on psychedelic and...
Results from two-combined studies have revealed that psilocybin-assisted therapy increased brain activity in people with depression for up to three weeks following use.
Entheon Biomedical has announced an improved genetic screening platform that includes the brain-derived neurotrophic factor (BDNF) gene.
Cybin Inc.
The first healthy, psychedelic-naïve volunteers have been dosed in Beckley Psytech’s Phase I clinical trial assessing safety and pharmacokinetics of its second innovative formulation of 5-MeO-DMT...
HMNC Brain Health and Develco Pharma have announced promising top-line results from the Phase II proof-of-concept investigator-initiated trial of its oral prolonged-release formulation of ketamine (KET01)...
A new study has shown that higher ratings of mystical-type experiences induced by psychedelics were associated with greater increases in the attribution of consciousness.
Follow-up data from a Phase III clinical trial shows that MDMA therapy could hold promise for millions suffering from the condition.
Cybin Inc.